Related Experiment Video
Updated: Aug 11, 2026
11:27
Modeling Spontaneous Metastatic Renal Cell Carcinoma (mRCC) in Mice Following Nephrectomy
Published on: April 29, 2014
Targeted therapy for metastatic renal cell carcinoma
P H Patel1, R S K Chaganti, R J Motzer
1Department of Medicine, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA.
British Journal of Cancer
|February 9, 2006
Summary
Metastatic renal cell carcinoma (RCC) treatment is evolving. Novel targeted therapies, including tyrosine kinase inhibitors and monoclonal antibodies, show promise in early studies for this historically difficult-to-treat cancer.
Area of Science:
- Oncology
- Translational Medicine
Background:
- Metastatic renal cell carcinoma (RCC) exhibits resistance to traditional therapies.
- Limited efficacy observed with interleukin-2 and interferon-alpha in a subset of patients.
Purpose of the Study:
- To review renal cell carcinoma (RCC) biology.
- To explore the development of novel targeted therapies for metastatic RCC based on biological understanding.
Main Methods:
- Review of existing literature on RCC biology.
- Analysis of ongoing clinical trials for targeted agents.
Main Results:
- Emerging targeted therapies include small molecule tyrosine kinase inhibitors, monoclonal antibodies, and novel agents.
- Phase II studies indicate promising activity for sunitinib, sorafenib, and bevacizumab.
Conclusions:
- Targeted therapies represent a significant advancement in metastatic RCC treatment.
- Phase III study results are crucial to define the role of these novel agents in clinical practice.
Related Concept Videos
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...